[{"id":"afef0721-8e8b-4e9e-b3e0-4b699e32e056","acronym":"OPERA","url":"https://clinicaltrials.gov/study/NCT03326102","created_at":"2021-01-18T16:25:31.533Z","updated_at":"2024-07-02T16:35:19.038Z","phase":"Phase 2","brief_title":"Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer","source_id_and_acronym":"NCT03326102 - OPERA","lead_sponsor":"Daehwa Pharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Liporaxel (paclitaxel oral)"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 07/06/2018","start_date":" 07/06/2018","primary_txt":" Primary completion: 12/13/2022","primary_completion_date":" 12/13/2022","study_txt":" Completion: 12/13/2022","study_completion_date":" 12/13/2022","last_update_posted":"2024-02-16"}]